EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL 28.09.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release BOS.
Gamida Cell (GMDA) Announces Long-Term Data from Omidubicel Phase 3 Trial Demonstrates OS and Sustainable Durable Outcomes for Patients with Blood Cancers streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BOSTON - MorphoSys USA, Inc., a fully owned subsidiary of MorphoSys AG , announced data from the ongoing L-MIND study showing that Monjuvi plus lenalidomide followed by Monjuvi monotherapy provided. | September 29, 2022
MorphoSys AG (MOR) Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi for Patients with R/R DLBCL streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.